Health Secretary Wes Streeting has issued a stern warning to the Conservative party over its stance on gender identity services, urging his own party to maintain a cross-party consensus that was established before last year's election. In a letter to opposition leader Kemi Badenoch, Streeting called for "the heat and ideology" to be taken out of the debate surrounding a trial on puberty blockers for children.
The trial, which is set to study over 200 children with gender identity conditions, has sparked controversy within the party. Badenoch and shadow health secretary Stuart Andrew had expressed concerns about the NHS's support for a clinical trial involving drugs that halted natural puberty, citing "remarkably weak" evidence on the treatment's effectiveness.
However, Streeting argues that only a clinical trial can determine whether the treatment is effective in treating gender-related distress, adding that there is no good evidence on long-term outcomes. He stressed the importance of taking "the heat and ideology out of this issue" to ensure children's health is led by evidence and medical expertise.
Streeting also highlighted the need for proper control groups in the trial, which he claims will not be present due to the opposition's concerns. He argued that a group of young people not receiving puberty blockers would also be studied and compared to trial participants with respect to outcomes.
The controversy surrounding the trial has sparked debate about the nature of gender identity services for under 18s in England. The issue was previously addressed by leading paediatrician Hilary Cass, who recommended a puberty blocker trial as part of a wider research programme.
The trial, which is set to study over 200 children with gender identity conditions, has sparked controversy within the party. Badenoch and shadow health secretary Stuart Andrew had expressed concerns about the NHS's support for a clinical trial involving drugs that halted natural puberty, citing "remarkably weak" evidence on the treatment's effectiveness.
However, Streeting argues that only a clinical trial can determine whether the treatment is effective in treating gender-related distress, adding that there is no good evidence on long-term outcomes. He stressed the importance of taking "the heat and ideology out of this issue" to ensure children's health is led by evidence and medical expertise.
Streeting also highlighted the need for proper control groups in the trial, which he claims will not be present due to the opposition's concerns. He argued that a group of young people not receiving puberty blockers would also be studied and compared to trial participants with respect to outcomes.
The controversy surrounding the trial has sparked debate about the nature of gender identity services for under 18s in England. The issue was previously addressed by leading paediatrician Hilary Cass, who recommended a puberty blocker trial as part of a wider research programme.